| Popis: |
Fluoropyrimidines are commonly used in clinical oncology, but their strong dose-dependent toxicity limits therapeutic application. The synthetic derivative 5′-deoxy-5-fluorouridine (5′-dFUrd) [1] has raised marked interest due to a higher therapeutic index as compared with 5-fluorouracil (5-FUra) or other related compounds [2–4]. It is also a less potent leukopenia inducer [2, 5] and is not as strongly immunosuppressive as other fluoropyrimidines [6, 7]. The biological activity of this pro-drug is dependent upon its enzymatic cleavage to 5-FUra by a pyrimidine Phosphorylase [8–10] which is found in much higher levels in human and animal tumours than in normal tissues, except in the intestinal tract [3, 4, 10–12]. |
